autoimmune gastritis
Conditions
Interventions
None listed
Sponsors
Graduate School of Medicine, The University of Tokyo, Center for Epidemiology and Preventive Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Case with confirmed diagnosis of AIG 2) Case with confirmed diagnosis of active HP infection 3) Case without chronic gastritis by endoscopy and inapplicable to 1),2)
Exclusion criteria
Exclusion criteria: -Cases with medical history of H. pylori eradication treatment -Cases with regular use of proton pomp inhibitor (PPI) / potassium-competitive acid blocker (P- CAB) -Cases with medical history of surgical operation of the upper digestive tract -Cases with medical history of malignant disease (last 5 years, with the exception of intramucosal cancer cured by local treatment) -Patients with hereditary gastrointestinal tumor diseases (familial adenomatous polyposis, Lynch syndrome, hereditary nonpolyposis colorectal cancer, Peutz-Jeghers syndrome, Cowden syndrome, hereditary diffuse gastric cancer etc.) -Cases with use of 2 or more antiplatelet drugs or anticoagulants, or with coagulation abnormalities -Cases with regular use of steroids -Minor/elderly person/handicapped person who require special consideration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene expression profiling and epigenetic analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| Statistical analysis associated with the risk of neoplasm emergence | — |
Countries
Japan
Contacts
Public ContactKeiko Niimi
Graduate School of Medicine, The University of Tokyo Center for Epidemiology and Preventive Medicine
Outcome results
None listed